Actinium snatches up ex-Novartis clinical manager
pharmafile | November 29, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Actinium, Novartis, appointment
Actinium Pharmaceuticals has appointed Gregory Bergonio to the position of director of Clinical Operations, where he will first guide the progress of the company’s current Actimab-A Phase 2 clinical trial, a 53-patient study investigating the efficacy of Actimab-A in inducing remissions in elderly sufferers of acute myeloid leukaemia (AML).
The New York-based biopharmaceutical firm’s primary remit lies on the development of targeted immunotherapies for advanced cancers for which there is unmet or ineffective alternative treatment, and Bergonio will aid in the advancement of the company’s existing and future trials.
Bergonio previously held the role of an expert clinical manager in Novartis’ oncology global development unit with a focus on AML, and so brings to the role an expansive experience of managing operations at clinical trials sites on an international level. Earlier in his career, Bergonio has served a number of CRO and pharma companies including Bausch & Lomb, OSI, Forest Laboratories and Kern McNeill.
“We are very excited to welcome Greg to the clinical development team at Actinium,” remarked Sandesh Seth, Actinium’s executive chairman. “Greg’s joining comes at an ideal time given our increased development efforts as a result of the Actimab-A Phase 2 trial and Iomab-B pivotal Phase 3 SIERRA trial. Greg’s direct experience in AML and significant knowledge of clinical trial management will have an immediate impact on our capabilities that we expect will add efficiency and scale to our current and planned clinical development efforts.”
Related Content
Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …
Novartis candidate for Sjögren’s disease presents positive results
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …
First malaria medicine for infants under 4.5kg receives approval
Coartem (artemether-lumefantrine) Baby, or Riamet, has been approved by Swissmedic as the first malaria medicine …
